1. Generics Bulletin
  2. >>Content

What’s Next? Five Things To Look Out For In June

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

What's Next Image
Source: Norstella/Citeline

Today, 1 June, Celltrion’s Stoboclo and Osenvelt (denosumab-bmwo) biosimilars – approved by the FDA in February – are set to follow Sandoz’s late May entry into the US denosumab market.

Under the terms of a settlement reached with Amgen earlier this year that paved the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Content

What’s Next? Five Things To Look Out For In October

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for October 2025.

What’s Next? Five Things To Look Out For In September

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for September 2025.

What’s Next? Five Things To Look Out For In August

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for August 2025.

What’s Next? Five Things To Look Out For In July

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for July 2025.

More from Generics Bulletin

Formycon And Teva Eye Ranibizumab Advantage With European PFS Launch

 
• By Dave Wallace

Partners Formycon and Teva are hoping to gain an advantage in the European ranibizumab market by launching a unique pre-filled syringe formulation of their partnered Lucentis biosimilar.

Celltrion Settlement Provides US Date For Aflibercept Entry

 
• By Dave Wallace

Just days after receiving FDA approval for its Eydenzelt biosimilar rival to Eylea, Celltrion has secured a US aflibercept launch date through a settlement with originator Regeneron. Meanwhile, new launches have helped to boost the Korean firm’s financials in Q3.

Aspire Builds Out UK Business With Charlwood Acquisition

 
• By Dave Wallace

Aspire Pharma is expanding again, with the acquisition of fellow UK firm and niche generics developer Charlwood Pharma.